All In Biotech

Drug Trial Radar · NCT07307638

Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ZT006 as Well as the Food Effect on the Pharmacokinetics of ZT006 in Healthy, Overweight and Obese Participants

Last checked: Nov 19, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Nov 28, 2024

Primary completion

Jun 14, 2025

Study completion Jun 24, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

ZT006 is an oral, long-acting glucagon-like peptide-1. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 in healthy, overweight and obese participants. The study comprises three parts, i.e. single dose-escalation, multiple dose-escalation, food effect on the pharmacokinetics of ZT006. In the single dose-escalation study, participants will receive a single dose (ZT006 dose level 1 - 5 or corresponding placebo) of ZT006 under fasted condition. A higher dose can only be given after obtaining acceptable safety and tolerability data for at least 7 days after the previous dose. After study drug administration, there will be a 7-day in-house period for safety observation and pharmacokinetics samples collection. Participants will join ambulatory visits until 42 days post-dose. In the multiple dose-escalation study, participants will receive a daily dose of ZT006 or corresponding placebo over 42 days in a dose up-titration fashion according to the following regimen: * Cohort 1: dose level 1 - dose level 2 - dose level 3 * Cohort 2: dose level 1 - dose level 2 - dose level 3 - dose level 4 * Cohort 3: dose level 2 - dose level 3 - dose level 4 * Cohort 4: dose level 2 - dose level 3 - dose level 4 - dose level 5 Dosing of a cohort with higher drug exposure can only be done after evaluation of safety and tolerability data for at least 14 days after the first dose in the previous cohort. Participants will join ambulatory visits until 35 days after the last dose. To evaluate the food effect on the pharmacokinetics of ZT006, participants who have received single dose of ZT006 or placebo of dose level 4 in the single dose-escalation study will receive another dose of ZT006 or placebo after a high fat, high caloric breakfast.

Conditions

  • Overweight,Obesity

Interventions

  • ZT006Drug

    Participants will receive a single dose of ZT006 of dose level 1 under fasted condition.

  • ZT006Drug

    Participants will receive a single dose of ZT006 of dose level 2 under fasted condition.

  • ZT006Drug

    Participants will receive a single dose of ZT006 of dose level 3 under fasted condition.

  • ZT006Drug

    Participants will receive a single dose of ZT006 of dose level 4 under fasted condition in period 1, and after a high fat, high caloric breakfast in period 2.

  • ZT006Drug

    Participants will receive a single dose of ZT006 of dose level 5 under fasted condition.

  • ZT006Drug

    Participants will receive daily doses of ZT006 for 42 days: dose level 1 for 7 days, then dose level 2 for 7 days, then dose level 3 for 28 days.

  • ZT006Drug

    Participants will receive daily doses of ZT006 for 42 days: dose level 1 for 7 days, then dose level 2 for 7 days, then dose level 3 for 14 days, then dose level 4 for 14 days.

  • ZT006Drug

    Participants will receive daily doses of ZT006 for 42 days: dose level 2 for 7 days, then dose level 3 for 7 days, then dose level 4 for 28 days.

  • ZT006Drug

    Participants will receive daily doses of ZT006 for 42 days: dose level 2 for 7 days, then dose level 3 for 7 days, then dose level 4 for 14 days, then dose level 5 for 14 days.

  • Placebo of ZT006Drug

    Participants will receive a single dose of placebo of ZT006 under fasted condition.

  • Placebo of ZT006Drug

    Participants will receive a single dose of placebo of ZT006 under fasted condition in period 1, and after a high fat, high caloric breakfast in period 2.

  • Placebo of ZT006Drug

    Participants will receive daily doses of placebo of ZT006 for 42 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of treatment-emergent adverse events after single dose administration under fasted condition.Time frame: From baseline to Day 43
  2. Rate of treatment-emergent adverse events during and after multiple-dose administration.Time frame: From baseline to end of study (Day 77)
  3. Rate of treatment-emergent adverse events after single dose administration under fed condition.Time frame: From Day 44 to end of study (Day 86)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.